DE69131718T2 - Aus leber angereicherter transkriptionsfaktor - Google Patents

Aus leber angereicherter transkriptionsfaktor

Info

Publication number
DE69131718T2
DE69131718T2 DE69131718T DE69131718T DE69131718T2 DE 69131718 T2 DE69131718 T2 DE 69131718T2 DE 69131718 T DE69131718 T DE 69131718T DE 69131718 T DE69131718 T DE 69131718T DE 69131718 T2 DE69131718 T2 DE 69131718T2
Authority
DE
Germany
Prior art keywords
hnf
liver
protein
transcription
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131718T
Other languages
English (en)
Other versions
DE69131718D1 (de
Inventor
Frances Sladek
Weimin Zhong
James Darnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of DE69131718D1 publication Critical patent/DE69131718D1/de
Application granted granted Critical
Publication of DE69131718T2 publication Critical patent/DE69131718T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
DE69131718T 1990-12-21 1991-12-23 Aus leber angereicherter transkriptionsfaktor Expired - Fee Related DE69131718T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63172090A 1990-12-21 1990-12-21
PCT/US1991/009733 WO1992011365A1 (en) 1990-12-21 1991-12-23 Liver enriched transcription factor

Publications (2)

Publication Number Publication Date
DE69131718D1 DE69131718D1 (de) 1999-11-18
DE69131718T2 true DE69131718T2 (de) 2000-03-02

Family

ID=24532451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131718T Expired - Fee Related DE69131718T2 (de) 1990-12-21 1991-12-23 Aus leber angereicherter transkriptionsfaktor

Country Status (8)

Country Link
US (4) US5604115A (de)
EP (1) EP0564592B1 (de)
JP (1) JPH06505152A (de)
AT (1) ATE185598T1 (de)
AU (1) AU665939B2 (de)
CA (1) CA2098838C (de)
DE (1) DE69131718T2 (de)
WO (1) WO1992011365A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000087A2 (en) * 1994-06-24 1996-01-04 Akzo Nobel N.V. Kit for pretargeting and novel pretargeting conjugates
US5795726A (en) * 1996-11-12 1998-08-18 Millennium Pharmaceuticals, Inc. Methods for identifying compounds useful in treating type II diabetes
US5800998A (en) * 1996-11-12 1998-09-01 Millennium Pharmaceuticals, Inc. Assays for diagnosing type II diabetes in a subject
AU5257198A (en) * 1996-11-15 1998-06-03 Millennium Pharmaceuticals, Inc. Compositions and methods for treating type ii diabetes involving hnf-4
WO1998023780A1 (en) * 1996-11-26 1998-06-04 Joslin Diabetes Center, Inc. Methods for diagnosing and treating diabetes
EP0939084A1 (de) * 1998-02-11 1999-09-01 Ramanath B. Rao Östrogenbindungproteinverbindung, ihre mögliche Rolle in Östrogenwirkung und potentielle Verwendung
US6324479B1 (en) 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
AU2898300A (en) * 1999-02-26 2000-09-21 Gary Levy Modulators of fgl2 prothrombinase
US20040062770A1 (en) * 1999-02-26 2004-04-01 Gary Levy Modulators of fgl2 prothrombinase
AU2001278496A1 (en) * 2000-07-21 2002-02-05 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
US20030082561A1 (en) * 2000-07-21 2003-05-01 Takashi Sera Zinc finger domain recognition code and uses thereof
US7790690B2 (en) 2000-10-11 2010-09-07 U.S. Department Of Veterans Affairs Glucose sensitive regulator of insulin transcription
WO2002059621A2 (en) * 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
WO2002072874A1 (fr) * 2001-03-14 2002-09-19 Fujisawa Pharmaceutical Co., Ltd. Procede de criblage d'un agoniste hnf4$g(a)
US7033790B2 (en) * 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7572242B2 (en) * 2004-03-22 2009-08-11 Alcon, Inc. Method of operating an ultrasound handpiece
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
EP2015758B1 (de) * 2006-05-05 2014-04-02 Isis Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation der expression von apo-b
AU2008230886B9 (en) 2007-03-24 2014-09-04 Kastle Therapeutics, Llc Administering antisense oligonucleotides complementary to human apolipoprotein B
WO2010107838A1 (en) 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
EP2521785B1 (de) * 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
CN103547271A (zh) 2011-04-27 2014-01-29 Isis制药公司 载脂蛋白ciii（apociii）表达的调节
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2018256436A1 (en) 2017-04-19 2019-11-07 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5091518A (en) * 1989-11-16 1992-02-25 The Salk Institute For Biological Studies Beta retinoic acid response elements compositions and assays

Also Published As

Publication number Publication date
US6500672B1 (en) 2002-12-31
DE69131718D1 (de) 1999-11-18
US6025196A (en) 2000-02-15
EP0564592A1 (de) 1993-10-13
US5604115A (en) 1997-02-18
EP0564592B1 (de) 1999-10-13
AU9174291A (en) 1992-07-22
AU665939B2 (en) 1996-01-25
US5849485A (en) 1998-12-15
CA2098838A1 (en) 1992-06-22
ATE185598T1 (de) 1999-10-15
JPH06505152A (ja) 1994-06-16
CA2098838C (en) 2002-11-26
WO1992011365A1 (en) 1992-07-09

Similar Documents

Publication Publication Date Title
DE69131718D1 (de) Aus leber angereicherter transkriptionsfaktor
Aguet High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor
Werner et al. Transcriptional repression of the insulin-like growth factor I receptor (IGF-IR) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-IR gene transcription start site.
Herve et al. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1‐acid glycoprotein.
Roesler et al. Identification of multiple protein binding domains in the promoter-regulatory region of the phosphoenolpyruvate carboxykinase (GTP) gene
Singh et al. High mobility group proteins 1 and 2 function as general class II transcription factors
Renz et al. Purification and molecular cloning of the scaffold attachment factor B (SAF-B), a novel human nuclear protein that specifically binds to S/MAR-DNA
Jenke et al. An episomally replicating vector binds to the nuclear matrix protein SAF‐A in vivo
Asa et al. Molecular determinants of pituitary cytodifferentiation
Hiroi et al. Bisphenol A binds to protein disulfide isomerase and inhibits its enzymatic and hormone-binding activities
Carson et al. Structure-function properties of the chicken progesterone receptor A synthesized from complementary deoxyribonucleic acid
Bogenhagen Interaction of mtTFB and mtRNA Polymerase at Core Promoters for Transcription of Xenopus laevis mtDNA (∗)
Shephard et al. Quantification of cytochrome P450 reductase gene expression in human tissues
PARK et al. The CYP2B1 proximal promoter contains a functional C/EBP regulatory element
Thomas et al. Growth hormone rapidly activates rat serine protease inhibitor 2.1 gene transcription and induces a DNA-binding activity distinct from those of Stat1,-3, and-4
Borthwick et al. Purification and immunochemical characterization of a male-specific rat liver oestrogen sulphotransferase
Reel et al. Oestrogen-inducible uterine progesterone receptors. Characteristics in the ovariectomized immature and adult hamster
Kajiyama et al. Regulation of α-fetoprotein expression by Nkx2. 8
Clark The cellular distribution of steroid hormone receptors: have we got it right?
Beck et al. Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system
Amaral et al. Human liver nuclear transcortin its postulated role in glucocorticoid regulation of genetic activity
Ikonen et al. Heterodimerization is mainly responsible for the dominant negative activity of amino‐terminally truncated rat androgen receptor forms
Hayward et al. A middle-affinity estrogen-specific binding protein in livers of vitellogenic and nonvitellogenic Xenopus laevis
Newton et al. Involvement of the estrogen receptor in the growth response of pituitary tumor cells to interleukin-2
Aoki et al. A western blotting procedure for detection of metallothionein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee